Christian T. Ruff, MD, MPH, of Brigham and Women's Faulkner Hospital, discusses new data comparing abelacimab with ...

MACRO trial researchers said adapting to the COVID-19 pandemic mid-trial may have undercut the efficacy of the intervention, ...

Findings from the American College of Cardiology 2025 Annual Scientific Session show oral semaglutide reduces the risk of heart attack, stroke, and cardiovascular death by 14% in patients with type 2 ...

STRIDE investigator Marc Bonaca, MD, MPH, University of Colorado School of Medicine, highlights how the data could provide insight into peripheral artery disease and type 2 diabetes treatment options.

Despite showing no overall benefit, the in-home paramedic visit appeared to help women avoid readmissions more than men.

Researchers suggest the 20% reduction in nonfatal heart attacks was the primary driver of this benefit for patients with type ...

Late-breaking data showed almost all patients achieved normal blood clotting and vessel repair after bentracimab infusion.

Hispanic and Latino adults found that while preserving cultural identity may initially benefit health, socioeconomic factors ...

Five abstracts showcase critical insights into women’s cardiovascular health, highlighting rising maternal mortality, ...

Medication nonadherence to oral anticoagulants and oral anti–prostate cancer medication has been scrutinized through new ...

Erythropoiesis-stimulating agent (ESA) treatment before or early after regular transfusion therapy improved overall survival ...

While the overall effectiveness of collaborative care has been well established, this study aimed to determine which specific ...